$3.2M BioAffinity Offering Closes: WallachBeth Capital Facilitates…

Event summary

$3.2M offering closed for bioAffinity Technologies via WallachBeth Capital on June 18, 2026.
4 million shares of common stock (or pre-funded warrants) sold at $0.80 per share ($0.793 per warrant).
Proceeds to support development of noninvasive lung cancer detection tests.
WallachBeth acted as sole placement agent for the transaction.

The big picture

This $3.2M offering reflects growing investor interest in early-stage cancer diagnostics, particularly noninvasive solutions. The deal underscores WallachBeth's niche focus on healthcare capital markets, where smaller biotechs increasingly rely on specialized placement agents to access public funding. The transaction comes amid heightened competition in lung cancer detection, where accuracy and cost-efficiency are key differentiators.

What we're watching

Execution Risk: How bioAffinity will deploy the $3.2M to accelerate its noninvasive lung cancer detection technology.
Market Positioning: Whether this funding round positions bioAffinity competitively against larger diagnostics players.
Capital Markets Strategy: The pace at which WallachBeth Capital can facilitate additional healthcare sector financings.